|
Preadmission comorbidities and types admission of the study cohort |
|||
| Control group (n = 7,626) |
Corticosteroid exposure group (n = 2,632) |
P |
|
|
|
|||
| Age (years) |
72 (48–84) |
67 (43–82) |
0.0001 |
| Female |
2,860 (38) |
1,147 (44) |
0.0001 |
| Body mass index (kg/m2) |
26 (20–35) |
26 (20–35) |
0.8 |
| Peripheral arterial disease |
777 (10) |
221 (8) |
0.008 |
| Cerebral vascular disease |
159 (2) |
23 (1) |
0.0001 |
| Neurological disease (degenerative brain disease) |
1,048 (14) |
396 (15) |
0.1 |
| Congestive heart failure |
974 (13) |
361 (14) |
0.2 |
| Hypertension |
3,687 (48) |
995 (38) |
0.0001 |
| Diabetes mellitus |
1,359 (18) |
436 (17) |
0.1 |
| Liver disease |
636 (8) |
351 (13) |
0.0001 |
| Malignancy |
1,179 (15) |
685 (26) |
0.0001 |
| Chronic obstructive pulmonary disease |
870 (11) |
565 (21) |
0.0001 |
| Pulmonary disease (restrictive and obstructive) |
1,025 (13) |
663 (25) |
0.0001 |
| Renal disease |
577 (8) |
223 (8) |
0.9 |
| Connective tissue disease |
88 (1) |
197 (7) |
0.0001 |
| Cachexia |
157 (2) |
126 (5) |
0.0001 |
| Charlson comorbidity score |
1 (0–4) |
2 (0–5) |
0.0001 |
| Indications for corticosteroids |
|||
| Relative adrenal insufficiency |
- |
1,022 (39) |
- |
| Anti-inflammatory action |
- |
1,270 (48) |
- |
| Immunosuppression |
- |
340 (13) |
- |
| Types of admission |
|||
| Coronary care unit |
1,561 (20) |
211 (8) |
0.0001 |
| Medical |
2,623 (34) |
1,168 (44) |
0.0001 |
| Surgical |
3,442 (46) |
1,253 (48) |
0.1 |
|
Data presented as median (10–90% percentiles) or actual numbers (percentage). | |||
Rady et al. Critical Care 2006 10:R101 doi:10.1186/cc4971 |
|||